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Abstract
Background: A commonly reported problem with the conduct of multicentre randomised
controlled trials (RCTs) is that recruitment is often slower or more difficult than expected, with
many trials failing to reach their planned sample size within the timescale and funding originally
envisaged. The aim of this study was to explore factors that may have been associated with good
and poor recruitment in a cohort of multicentre trials funded by two public bodies: the UK Medical
Research Council (MRC) and the Health Technology Assessment (HTA) Programme.
Methods: The cohort of trials was identified from the administrative databases held by the two
funding bodies. 114 trials that recruited participants between 1994 and 2002 met the inclusion
criteria. The full scientific applications and subsequent trial reports submitted by the trial teams to
the funders provided the principal data sources. Associations between trial characteristics and
recruitment success were tested using the Chi-squared test, or Fisher's exact test where
appropriate.
Results: Less than a third (31%) of the trials achieved their original recruitment target and half
(53%) were awarded an extension. The proportion achieving targets did not appear to improve
over time. The overall start to recruitment was delayed in 47 (41%) trials and early recruitment
problems were identified in 77 (63%) trials. The inter-relationship between trial features and
recruitment success was complex. A variety of strategies were employed to try to increase
recruitment, but their success could not be assessed.
Conclusion: Recruitment problems are complex and challenging. Many of the trials in the cohort
experienced recruitment difficulties. Trials often required extended recruitment periods
(sometimes supported by additional funds). While this is of continuing concern, success in
addressing the trial question may be more important than recruitment alone.
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Background
Randomised controlled trials (RCTs) are widely accepted
as the gold standard for evaluating healthcare interven-
tions [1,2] and decision makers are increasingly looking
to the results of RCTs to guide practice. RCTs are a major,
increasing component of both NHS-supported and non-
commercially funded research[3]. Recruitment is often
slower or more difficult than expected, with many trials
failing to reach their planned sample size within the
timescale and funding originally envisaged. If the target
sample size is not achieved, results will usually be less reli-
able. If recruitment has to be extended to reach the
required sample size, this usually costs more and the use
of the results in clinical practice will be delayed.
The reasons why certain trials recruit well while others do
not remain unclear[4]. To investigate this the UK NHS
R&D National Methodology Programme and the UK
Medical Research Council (MRC) funded a project – Strat-
egies for Trials Enrolment and Participation Study
(STEPS) considering three aspects of recruitment: a review
of a cohort of trials funded by both organisations; case
studies of trials which appeared to have particularly inter-
esting lessons for recruitment (exemplars); and an in-
depth case study of one large multicentre trial to examine
the feasibility of applying a business-orientated analytical
framework. This paper describes the review of the cohort
of trials, which explored factors that may have influenced
recruitment and concentrated on issues relating to the
researchers and clinicians conducting the trials. Full
details of the project are published elsewhere[5].
The objectives of the review were to:
• characterise the trials in terms of the settings, interven-
tions and outcomes studied;
• characterise the factors thought likely to affect success of
recruitment including level of funding, complexity of trial
design, involvement of a trials support unit etc;
• describe patterns of recruitment (such as to original plan
or better, slower start than anticipated, recruitment with
identifiable change-points etc); and
• note trialists' reports of factors perceived to be associated
with good or poor recruitment (eg delays in obtaining
funding or research ethics approval) and strategies
attempted to improve recruitment.
Methods
Trial identification
Trials were identified from the administrative databases
held by the two funding bodies. Trials were eligible for
inclusion if:
• they involved more than one clinical centre;
• recruitment started on or after 1 January 1994 (this cut-
off was chosen as the HTA Programme was established
during 1993); and
• recruitment was originally planned to close on or before
31 December 2002. Trials that were awarded an extension
to the recruitment phase beyond 31 December 2002 were
included if they had closed to recruitment at the time of
data extraction.
Cluster trials were excluded as recruitment issues are often
different compared with individually randomised tri-
als[6].
Development of hypotheses
A priori hypotheses were developed about factors that
might affect recruitment, related to issues in previous lit-
erature reviews [4] and insights gained from the MRC clin-
ical trials enquiry[7].
Data extraction
Application forms and progress reports were examined at
the central offices of the two funders following notifica-
tion to the appropriate principal investigators (PIs).
Access was subject to confidentiality safeguards.
A data extraction form was developed to facilitate system-
atic collection of information under six main topic head-
ings: 1) trial identifying details; 2) trial administrative
details (eg dates of commencement, start of recruitment);
3) trial features (eg if there was a formal pilot phase, if
there was a dedicated trial manager); 4) finance; 5)
recruitment summary (eg original target, any revisions,
final recruitment numbers); and 6) description of delay or
failure to reach recruitment targets (eg any delays to
recruitment, strategies used to improve recruitment). The
data extraction form and procedures were piloted on eight
trials. Minor modifications were made before proceeding.
Where information was not recorded or unclear, reports
of the specific trials held on the Current Controlled Trials
meta-register of randomised trials http://www.controlled-
trials.com and the NCCHTA website http://
www.ncchta.org were searched to augment the dataset.
Some PIs and trial managers were also asked to provide
additional information.
Results
One hundred and fourteen trials fulfilled the inclusion
criteria. Forty-one (36%) trials were funded by the HTA
Programme and 73 (64%) by the MRC. Five of these,
although presented under single project banners, were
found to represent a number of sub-trials, each with their
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own individual sample size targets and individual recruit-
ment issues. For the purposes of describing the trial fea-
tures, the denominator is based on the number of
recorded 'projects', ie 114, to reflect the fact that trial
teams were common across sub-trials. For the analysis of
recruitment issues, however, we treated the sub-trials sep-
arately, using the denominator of 122 trials.
Overall trial features
Table 1 describes features of the trials. Sixty trials (53%)
had conducted a formal pilot study. Of these, 32 indicated
the pilot study had led to a change in recruitment strategy
for the main trial. The most common changes noted were
that: written trial materials were modified (8 trials); the
trial design was changed (6 trials); changes were made to
the inclusion criteria (4 trials); the recruitment target was
changed (4 trials); and, the number of sites was increased
(4 trials). Most trials (78%) were conducted from a trials
unit and 92% involved multidisciplinary teams. No trial
had a consumer as a grant applicant although 9 trials had
some form of consumer involvement during the trial.
Funding ranged from £16 per planned participant to
£4522 with a median of £641. The trials in our cohort
started recruitment during the period 1994–2002. During
this time, most trials only included research costs. How-
ever for some early trials treatment/support costs were not
distinguishable from research costs due to the costing
structure used for grants at that time. Twenty-four (24/89,
29%) trials were awarded a 'good' level of funding
(defined as more than £1000 per planned participant, def-
inition generated through consensus with the project
management group members).
Individual trial features
Table 2 summarises the characteristics of the 122 trials,
including design features, clinical area, setting and inter-
ventions. The majority of the trials were simple parallel
group trials (113, 93%). Most were two-arm (94, 77%)
trials, mainly representing cancer (25, 20%), mental
health (21, 17%) and orthopaedics/rheumatology (21,
17%). Approximately half (64, 53%) of the trials were in
a hospital setting.
Recruitment
Recruitment targets varied from 60 to 66,000 participants.
Table 3 summarises actual recruitment in relation to these
targets. Thirty-eight (31%) trials 'successfully' recruited (!
100% of their original target). A further 29 (24%) trials
achieved a recruitment rate of greater than 80% but less
than 100% of their original target.
In 42 (34%) trials the recruitment target was revised dur-
ing the trial. The target was revised in a downward direc-
tion in 36 (86%) of the 42. Only 19 (19/42, 45%) trials
whose targets were revised were known to have success-
fully recruited to their new target.
Enrolment was halted before the formal end of the recruit-
ment period in 14 (14/122, 11%) trials. In 11 this deci-
sion related to poor recruitment. In the three others, early
termination followed a recommendation from a data
Table 1: Descriptive features of trials and disciplines represented amongst trial investigators
Trial feature Valid N Yes
 n (%)
No
 n (%)
Not known
 n (%)
Trial had pilot study 114 60 (53) 41 (36) 13 (11)
•Was pilot funded? 60 35 (58) 4 (7) 21 (35)
•Was there a change in 
recruitment strategy because 
of pilot study?
60 32 (53) 5 (8) 23 (39)
Trial co-ordinated from 
trials unit
114 89 (78) 25 (22)
Trial had dedicated trial 
manager
114 86 (75) 14 (12) 14 (12)
Trial had paid local staff 
available
114 61 (54) 31 (27) 22 (19)
Disciplines 113*
Multidisciplinary 104 (92) 9 (8)
Consumer - 113 (100)
Economics 66 (58) 47 (42)
HSR 35 (31) 78 (69)
Medical/Dentist 109 (96) 4 (3)
Nursing 22 (19) 91 (80)
Statistics 83 (73) 30 (26)
Other 17 (15) 96 (85)
* Data was missing for one trial
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monitoring committee that there were clear differences
between the trial groups. However, in two of these, the
recruitment period had already been extended beyond
that originally specified.
Sixty-six (54%) trials requested an extension to the trial
grant to complete the original trial and, in all but one,
either a time plus grant extension (42, 64%), a time-only
extension (15, 23%) or a supplementary grant only (8,
12%) was awarded. Thirteen trials recruited their original
target after a time extension.
Figure 1 describes recruitment success by year of trial com-
mencement. Six of the fifteen trials (40%) that com-
menced recruitment in 1994 recruited to, or above, 100%
of their original recruitment target. Lower proportions of
trials achieved their targets amongst those started in the
late 1990s.
Delays to recruitment
The start of recruitment was delayed in 47 (41%) of trials
(data not shown). Main reasons cited were: delays related
to central trial staff (11 trials); local research staff (11 tri-
als); and local clinical arrangements (seven trials). Other
reasons identified included: delays with ethics; supply of
study drugs/placebo; development of clinical guidelines
impacting on the trial; PI moving; adverse publicity about
research; and publication of conflicting research.
Eighty six (75%) trialists indicated at the application stage
that they had pre-identified trial centres. In 17 cases some
pre-identified centres did not participate as planned.
There was no common reason for this, although the issue
of problems with "treatment" and "service support" costs
were raised in three cases. Thirty-seven (32%) trialists
indicated that they encountered delay in bringing in some
of the pre-identified centres. Reported reasons included:
problems with costs/funding (13 trials); delays in the
recruitment of staff (12 trials); and changes with the Mul-
ticentre Research Ethics Committee (MREC) system (6 tri-
Table 3: Recruitment in trials
N n (%)
Recruited successfully 122
Yes 38 (31.1)
No 84 (68.9)
Was recruitment target revised 122
Yes 42 (34.4)
No 76 (62.3)
Missing 4 (3.3)
Final recruitment figure
Original target: 122
! 100% 38 (31.1)
! 80% but < 100% 29 (23.8)
< 80% 55 (45.1)
Revised target: 42
! 100% 19 (45.2)
! 80% but < 100% 15 (35.7)
< 80% 8 (19.1)
Table 2: Characteristics of the trials
Characteristic N n (%)
Design: 122
Parallel 113 (93)
Factorial 6 (5)
Partially randomised patient preference 3 (2)
Number of arms: 122
Two 94 (77)
Three 18 (15)
More than three 10 (8)
Clinical areas: 122
Cancer 25 (20)
Mental health (including neurosciences/
psychiatry/psychology)
21 (17)
Orthopaedics/rheumatology (including back pain) 21 (17)
Obstetrics & Gynaecology 9 (7)
Primary care 8 (7)
Cardiology 5 (4)
Gastroenterology 5 (4)
Incontinence/urology 5 (4)
HIV/AIDS 5 (4)
Other 18 (15)
Setting: 122
Hospital 64 (53)
General practice 26 (21)
Mixed 16 (13)
Community 7 (6)
Missing 9 (7)
Geographical spread: 122
Multiple regions 63 (52)
Regional 51 (42)
Missing 8 (7)
Any recruiting centres outside UK: 114
No 88 (77)
Yes 25 (22)
Missing 1 (1)
Interventions: 122
Medical (drugs, injections) excluding 
chemotherapy
37 (30)
Behavioural therapies (eg CBT with or without 
conventional drugs)
12 (10)
Different types of surgical intervention (including 
laparoscopic)
12 (10)
Chemotherapy 10 (8)
New services/treatment policy/information 
provision (eg support programmes)
9 (7)
Radiology (including ultrasound) 8 (7)
Medical instruments (eg metal stents, 
pacemakers, bandage types)
7 (6)
Surgery v alternative (eg conservative 
management, radiotherapy)
4 (3)
Alternative therapies (including complementary 
medicine, water-based therapies)
4 (3)
Other 19 (16)
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als). Fifty-two (45%) trials recruited new centres to ensure
the delivery of the trial.
Once centres were enrolled, early recruitment (within the
first 25% of scheduled recruiting time) was reported to be
slower than anticipated in 77 (63%) trials. Common rea-
sons for this were: fewer eligible patients than expected
(19 trials); internal problems eg with staff (18 trials); and
a smaller percentage of patients agreeing to participate
than was expected (16 trials). Other problems included:
eligible patients missed (10 trials); external problems eg
publicity (8 trials); funding issues (5 trials) and issues
with procedures/interventions eg randomisation or pla-
cebo (5 trials).
Delays to later recruitment (within the last approximate
75% of recruiting time) were reported in 46 (38%) trials.
The most common reasons noted in this phase were:
internal problems eg staff (10 trials); fewer patients agree-
ing to participate than expected (9 trials); fewer eligible
patients than anticipated (7 trials); and external prob-
lems, particularly with publicity (7 trials). Numerous
Recruitment success related to year trial commencedFigure 1
Recruitment success related to year trial commenced.
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other problems included: funding difficulties (5 trials);
conflicts with other trials (5 trials); and long waiting lists
(3 trials).
Relationships between trial features and successful 
recruitment
Trial features that were pre-specified as likely to enhance
the chances of successful recruitment are presented in
Table 4. An association suggesting that the factor
increased successful recruitment is indicated by an odds
ratio (OR) of greater than unity. Only trials for which the
information was known were included. Confidence inter-
vals (CIs) around the OR estimates were wide, reflecting
the maximum sample size (122). Some of the comparison
cells had very few data (eg number with a complex design
and number with consumer input). There were marginally
statistically significant associations with MRC funding,
being a cancer trial, and with not having paid local trial
coordinators.
Reported strategies for improving recruitment
Seventy-three trials reported using a variety of strategies to
improve recruitment (Table 5). The most common was
the use of newsletters and mail shots, both to clinical staff
and patients. Ten per cent of the trials reported that inclu-
sion criteria were changed or the protocol amended to
improve recruitment.
Discussion
Data from two historical cohorts of trials has shown that
failure to achieve projected targets for recruitment has
been common amongst multicentre trials supported by
the main funders of trials in the UK.
Fewer than one third recruited to 100% of their original
target, and 45% failed to recruit to within 80% of target.
Factors associated with successful recruitment were that
one or more intervention was only available inside the
trial, having a dedicated trial manager, and being a cancer
or a drug trial. These findings should be interpreted cau-
tiously; CIs were wide, associations were only marginally
statistically significant for some variables, and the trend
for some factors was towards a negative association. Com-
monly reported strategies to improve recruitment were
newsletters and mail shots, but it was not possible to
assess whether they were causally linked to changes in
recruitment.
The anticipated recruitment period was extended for
around half of trials, usually supported by a supplemen-
tary grant. Delays were experienced at all stages of recruit-
ment. The most commonly reported problem with early
recruitment was that fewer than expected eligible patients
were being observed. This phenomenon, known as "Lasa-
gna's Law" – where researchers and clinicians invariably
overestimate the number of patients available for study
participation – has been observed by a number of com-
mentators[8]. Factors thought to be potentially associated
with successful recruitment were relatively uninformative.
The CIs around the estimated ORs were all wide and too
imprecise to allow judgement about possible causal rela-
tionships.
A major strength of this study was that it included a sys-
tematically identified, complete cohort of trials funded by
the two major UK public funding bodies in the field of
health care and drew on previously confidential routine
progress reports submitted over the course of a trial by the
investigators. The trials represented a wide spectrum of
Table 4: Associations between features and recruitment success
Feature Valid N Trials with feature
that recruited
successfully* n (%)
Trials that didn't
have feature that
recruited
successfully* n (%)
Odds Ratio 95%CI p-value
Local recruitment coordinators 100 15/69 (22) 14/31 (45) 0.34 0.14, 0.84 0.017
Simple design 122 35/116 (30) 3/6 (50) 0.43 0.06, 3.41 0.374
Support from a trials unit 122 27/94 (29) 11/28 (39) 0.62 0.26, 1.50 0.289
Multidisciplinary input 113 34/104 (33) 3/9 (33) 0.97 0.19, 6.36 0.615
Pilot phase 109 18/66 (27) 11/43 (26) 1.09 0.46, 2.61 0.845
Good level of funding 89 7/24 (29) 17/65 (26) 1.16 0.41, 3.29 0.776
Drug trial 122 19/53 (36) 19/69 (28) 1.47 0.68, 3.18 0.326
Interventions only available inside the trial 112 7/18 (39) 26/94 (28) 1.66 0.58, 4.76 0.338
Consumer input 107 4/9 (44) 26/91 (29) 2.00 0.36, 10.05 0.446
Funded by the MRC 122 28/74 (38) 10/48 (21) 2.31 1.00, 5.36 0.048
Cancer trial 122 12/24 (50) 26/98 (27) 2.77 1.11, 6.93 0.026
Dedicated trial manager 107 32/91 (35) 2/16 (13) 3.80 0.79, 36.14 0.087
* ! 100% of original target
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clinical areas, clinical settings and geographical centres.
However, participants' perceptions of what makes a trial
attractive to join could not be elicited. The results of our
study complement the more in-depth qualitative investi-
gations which have tried to specifically address partici-
pants' perceptions[9-11].
Recruitment can be viewed as a surrogate measure of
other, less easily quantifiable, but arguably more signifi-
cant measures of trial success, such as 'impact on clinical
practice', or the extent to which the trial question has been
addressed. Other parameters should also be taken into
account, such as rates of participant retention and treat-
ment compliance.
We hoped to identify factors associated with successful
recruitment to provide a means of predicting or enhanc-
ing the chances of success. However, comparative analyses
yielded few insights, because of the choice of outcome
and exposure variables, and because of imprecision
around the estimates of association. Some factors (such as
the intervention only being available inside the trial, hav-
ing a dedicated trial manager, and being a cancer trial or a
drug trial) may be associated with successful recruitment,
these results were also (with the possible exception of can-
cer trials) compatible with there being no association.
Other analyses showed that some features expected to
enhance recruitment were less commonly observed in
'successful' trials than in unsuccessful trials. This applied
in particular to 'local paid recruitment coordinators', but
an alternative explanation for this negative association is
that the relationship comparison is confounded by other
factors such as the complexity of the trial and the years
when it was undertaken. As many of the variables are
potentially correlated a multivariable analysis would have
been desirable. We did not have sufficient power to
undertake this analysis – experts suggest that there should
be at least ten observations in the dataset for each poten-
tial explanatory variable to be included in the model[12].
As indicated above, there was evidence that cancer trials
were associated with better rates of successful recruitment
compared with non-cancer trials. The National Cancer
Research Network (NCRN) was established by the Depart-
ment of Health in April 2001 to improve the infrastruc-
ture within the NHS for clinical research in cancer in
England (most of the trials included in our study had
completed recruitment before this initiative had been
established). There has been a doubling of the recruit-
ment rate to cancer trials since the inception of the
NCRN[13]. Building on this success, the recently formed
UK Clinical Research Network http://www.ukcrn.org.uk
will continue the aim of improving the speed, quality and
integration of research, initially within the existing NHS
networks in cancer and mental health and new ones in the
priority areas of medicines for children, stroke, diabetes
and Alzheimer's disease.
Conclusion
This study highlights the challenges of recruiting to RCTs
and provides a valuable overview of trialists' attempts to
overcome them. Despite the growing literature summaris-
ing barriers and facilitators to recruitment published in
the 1990s (exemplified by the HTA review by Prescott [4])
only 55% of the trials recruited to within 80% of the orig-
inal target and the situation does not seem to have
improved over time. It is clear that recruitment to trials is
a complex problem. The two other components of STEPS
considering lessons from exemplar trials and from a busi-
ness perspective will be reported elsewhere.
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